<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Cysteine proteinase inhibitors stefin A and stefin B in operable carcinoma of the head and neck</dc:title><dc:creator>Strojan,	Primož	(Avtor)
	</dc:creator><dc:creator>Budihna,	Marjan	(Avtor)
	</dc:creator><dc:creator>Šmid,	Alojz	(Avtor)
	</dc:creator><dc:creator>Svetic,	Branka	(Avtor)
	</dc:creator><dc:creator>Vrhovec,	Ivan	(Avtor)
	</dc:creator><dc:creator>Kos,	Janko	(Avtor)
	</dc:creator><dc:creator>Škrk,	Janez	(Avtor)
	</dc:creator><dc:description>Purpose. To evaluate the significance of cysteine proteinase inhibitors stefins (Stefs) A and B for a treatment decision and prognosis in operable squamous cell carcinoma of the head and neck (SCCHN). Patients and methods. Stefs A and B concentrations were determined immunobiochemically using ELISAs in cytosols prepared from the tumor and adjacent normal mucosa from 91 patients with operable SCCHN. The median follow-up period of patients alive atthe close-out date was 5.8 years (range, 5-9.3 years). Results. Stef A concentrations were significantly higher in tumor compared to normal mucosa (FM.05). When a subgroup with clinically palpable nodes) at presentation was taken into consideration (n=57), a significant difference in Stef A (P=0.03) and Stef B (P=0.02) concentrations between those with negative and positive necks, as determined on histopathological examination, was observed. On the univariate survival analysis, higher Stefsć concentrations turned to be prognostically advantageous. Stef A proved its independent prognostic significance also on multivariate setting. Conclusions. With the capability todifferentiate between the pN0- and pN+-stages of the disease in the patientsoriginally presented as node-positive, Stefs A and B could be useful markers when deciding on the extent of neck surgery. In addition, both Stefs proved to be reliable prognosticators for survival in patients with operable SCCHN.</dc:description><dc:publisher>Slovenian Medical Association - Slovenian Association of Radiology, Nuclear Medicine Society, Slovenian Society far Radiotherapy and Oncology, and Slovenian Cancer Society </dc:publisher><dc:date>2002</dc:date><dc:date>2024-01-31 11:38:28</dc:date><dc:type>Neznano</dc:type><dc:identifier>18063</dc:identifier><dc:identifier>UDK: 577</dc:identifier><dc:identifier>ISSN pri članku: 1318-2099</dc:identifier><dc:identifier>COBISS_ID: 16895783</dc:identifier><dc:source>Ljubljana</dc:source><dc:language>sl</dc:language><dc:rights>by Authors</dc:rights></metadata>
